Glaukos (GKOS) vs Stevanato Group S.p.A. (STVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Glaukos (GKOS) has outperformed Stevanato Group S.p.A. (STVN) over the past year, gaining 104.8% versus a loss of 19.2%. Over five years, GKOS leads with a +284.2% price change compared with -20.1% for STVN. Glaukos is the larger company by market cap ($9.44 billion vs $5.31 billion), about 1.8 times the size.
On valuation, Stevanato Group S.p.A. trades at a lower forward P/E (23.3x vs 305.6x for Glaukos).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GKOS | STVN |
|---|---|---|
| Share price | $159.98 | $19.44 |
| Market cap | $9.44B | $5.31B |
| 1-day change | -7.09% | 0.00% |
| YTD return | +52.49% | -3.38% |
| 1-year return | +104.76% | -19.20% |
| 5-year return | +284.16% | -20.07% |
| P/E ratio (TTM) | — | 34.11 |
| Forward P/E | 305.56 | 23.30 |
| EPS (TTM) | $-3.26 | $0.57 |
| Dividend yield | 0.00% | 0.32% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $507.44M | — |
| Revenue growth (YoY) | +32.33% | — |
| Net income (latest FY) | $-187.69M | — |
| Gross margin | 55.72% | — |
| Operating margin | -39.33% | — |
| Net margin | -36.99% | — |
| 52-week high | $191.62 | $27.99 |
| 52-week low | $73.16 | $12.89 |
| Distance from 52-week high | -16.51% | -30.55% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +24.20% | +26.95% |
| Average volume | 798.61K | 370.27K |
| Shares outstanding | 58.98M | 49.83M |
| Employees | 1,094 | 6,010 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GKOS has outperformed STVN by 124.0 percentage points over the past year.
About Glaukos
GKOS stock →Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.
Health Care · Medical/Dental Instruments · 1,094 employees
About Stevanato Group S.p.A.
STVN stock →Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.
Health Care · Medical/Dental Instruments · 6,010 employees
GKOS vs STVN FAQ
Which is bigger, Glaukos or Stevanato Group S.p.A.?
Glaukos (GKOS) is larger, with a market capitalization of $9.44B compared with $5.31B for Stevanato Group S.p.A. (STVN).
Which stock has performed better over the past year, GKOS or STVN?
GKOS returned +104.76% over the past 12 months, compared with -19.20% for STVN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Glaukos or Stevanato Group S.p.A.?
Stevanato Group S.p.A. pays a dividend yielding 0.32%, while Glaukos does not currently pay a regular dividend.
Are Glaukos and Stevanato Group S.p.A. in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.